Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer.
Cancers of the upper GI tract, liver and pancreas have some of the poorest prognoses of any malignancies. Advances in diagnosis and treatment are sorely needed to improve the outcomes of patients. Nanotechnology offers the potential for constructing tailor-made therapies capable of targeting specific cancers. The particles themselves may be endowed with multifunctional properties that can be exploited for both diagnosis and treatment. Although development of therapies is still in the early stages, the use of nanoparticles (NPs) is widespread in diagnostic applications and will probably involve all areas of medicine in the future. Research into NPs is ongoing for upper gastrointestinal, liver and pancreatic cancers, and their use is becoming increasingly popular as contrast media for radiological investigations. Although more sophisticated technologies capable of active targeting are still in the early stages of assessment for clinical use, a small number of NP-based therapies are in clinical use.
Liverpool Cancer Research UK Centre, Department of Molecular and Clinical Cancer Studies, University of Liverpool, Daulby Street, Liverpool, L69 3GA, UK.
Paul D
PD
Sykes
John P
JP
Neoptolemos
Eithne
E
Costello
Christopher M
CM
Halloran
D004358:Drug Therapy / Q000639:trends; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000628:therapy; D055909:Magnetic Field Therapy / Q000639:trends; D050997:Nanomedicine / Q000639:trends; D036103:Nanotechnology / Q000639:trends*; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000628:therapy; D059016:Tumor Microenvironment